Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its ...

Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...

States argue that biological samples, DNA data, health-related traits and medical records are too sensitive to be sold without each person's express, informed consent.

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler presentations and more severe and prolonged lesions compared to patients with ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...